Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR2 | O43603 | 4/20 | 0.46 |
| ▸ | GALR1 | P47211 | 4/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | DKK1 | O94907 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3887686 | 0.95 | TRPV1 (0.47) | GALR2GALR1HSD11B1TRPV1DPP4 | |
| SCHEMBL3880207 | 0.93 | GALR2 (0.51) | GALR2GALR1HSD11B1TRPV1 | |
| SCHEMBL3876780 | 0.92 | GALR2 (0.46) | GALR2GALR1HSD11B1TRPV1 | |
| SCHEMBL3877834 | 0.90 | GALR2 (0.55) | GALR2GALR1HSD11B1TRPV1 | |
| SCHEMBL3885408 | 0.90 | GALR2 (0.55) | GALR2GALR1HSD11B1TRPV1 | |
| SCHEMBL3876607 | 0.90 | GALR2 (0.56) | GALR2GALR1HSD11B1TRPV1 | |
| SCHEMBL3881028 | 0.89 | GALR2 (0.44) | GALR2GALR1HSD11B1TRPV1 | |
| SCHEMBL3880119 | 0.89 | GALR2 (0.48) | GALR2GALR1HSD11B1TRPV1 | |
| SCHEMBL3888771 | 0.89 | HSD11B1 (0.46) | GALR2GALR1HSD11B1 | |
| SCHEMBL3884310 | 0.89 | TRPV1 (0.48) | GALR2GALR1TRPV1DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | GALR2 171/4885GALR1 270/4885HSD11B1 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.